AR044614A1 - Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4) - Google Patents
Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4)Info
- Publication number
- AR044614A1 AR044614A1 ARP040101943A ARP040101943A AR044614A1 AR 044614 A1 AR044614 A1 AR 044614A1 AR P040101943 A ARP040101943 A AR P040101943A AR P040101943 A ARP040101943 A AR P040101943A AR 044614 A1 AR044614 A1 AR 044614A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- hydroxy
- halogen
- ring
- Prior art date
Links
- 229940124530 sulfonamide Drugs 0.000 title abstract 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 title 1
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000003456 sulfonamides Chemical class 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 7
- 229910052717 sulfur Chemical group 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical class 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000001153 fluoro group Chemical group F* 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 3
- 239000001301 oxygen Chemical group 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- 239000011593 sulfur Chemical group 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- -1 Sulfonamide compounds Chemical class 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 101150020251 NR13 gene Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
- C07D241/22—Benzenesulfonamido pyrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Compuestos de sulfonamida, procesos e intermediarios utilizados en su preparación, composiciones farmacéuticas que los contienen y su uso para fines terapéuticos. Reivindicación 1: Un compuesto es caracterizado porque es de fórmula (1), o una sal aceptable para uso farmacéutico del mismo, donde: Ar1 es fenilo o tienilo, cada uno de los cuales está opcionalmente sustituido con entre uno y tres sustituyentes R1, R2 y R3 seleccionados entre halógeno, ciano, CF3, OCF3, O(C1-6) alquilo o C1-6 alquilo; R4 es C1-6 alcoxi donde el grupo alquilo puede formar un anillo saturado de entre 3 y 6 miembros o puede estar sustituido con entre 1 y 3 átomos de flúor o un grupo ciano; o O(C1-6)alquilR11, o O(C2-6)alquil-X-R11 donde el grupo alquilo puede formar un anillo saturado de entre 3 y 6 miembros y está sustituido opcionalmente con entre 1 y 3 grupos seleccionados entre hidroxi, halógeno, NR14R15, SR13, S(O)2R13, S(O)RB o COR13; uno de R5 o R6 es XCH2(C1-4)alquilo donde el grupo alquilo está sustituido en cualquier posición con los dos grupos R11 y NR1415 o hidroxi, o R5/R6 es XR16 donde R16 es un anillo de entre 4 y 8 miembros que contiene entre 1 y 3 heteroátomos seleccionados entre nitrógeno, oxígeno o azufre y está opcionalmente sustituido con entre 1 y 3 grupos seleccionados entre hidroxi, ciano, halógeno y =O, y R16 está sustituido con R11; y el otro es hidrógeno, halógeno, amino, NH(C1-6)alquilo, N((C1-6)alquil)2, C1-6 alcoxi o C1-6 alquilo opcionalmente sustituido con uno o más grupos flúor o hidroxilo; X es NR13, O, S, S(O), S(O)2, o un enlace; R11 es un grupo arilo o un anillo heteroaromático de entre 5 y 7 miembros que contiene entre 1 y 4 heteroátomos seleccionados entre nitrógeno, oxígeno o azufre, donde el grupo arilo o el anillo heteroaromático pueden estar opcionalmente sustituidos con entre 1 y 3 grupos seleccionados entre halógeno, C(O)NR14R15, C(O)OR12, hidroxi, =O, =S,CN, NO2, COR13NR14R15X(CH2)qNR14R15, (CH2)nNR14R15, (CH2)nOH, SR13, S(O)R13, S(O)2R13 (C1-6)alquil-X-(C1-6)alquilo, C1-6 alquilo o C1-6 alcoxi donde el grupo alquilo puede formar un anillo de entre 3 y 6 miembros o está sustituido opcionalmente con entre 1 y 3 grupos seleccionados entre hidroxi, halógeno, NR14R15, SR13, S(O)RB, S(O)2R13; o R11 es C(O)NR14R15, C(O)OR12, CH2OR12; R12 y R13 son en forma independiente hidrógeno o C1-6 alquilo donde el grupo alquilo puede estar sustituido con entre 1 y 3 átomos de flúor o puede formar un anillo saturado de entre 3 y 6 miembros; R14 y R15 son en forma independiente hidrógeno, C1-6 alquilo, C3-6 cicloalquilo, (CH2)gOH o (CH2)gNH2; o R14 y R15 junto con el átomo de nitrógeno al cual están unidos forman un anillo de entre 4 y 8 miembros que contiene 1 y 3 heteroátomos seleccionados entre nitrógeno, oxígeno y azufre y está opcionalmente sustituido con C1-6 alquilo, (C1-6)alquil-OH, o hidroxi; y n es 1, 2, 3, 4 ó 5; y q es 2, 3, 4, 5 ó 6, con la condición de que donde X es un enlace, entonces R5/R6 no es XCH2(C1-4)alquilR11.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0301653A SE0301653D0 (sv) | 2003-06-05 | 2003-06-05 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR044614A1 true AR044614A1 (es) | 2005-09-21 |
Family
ID=29212392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040101943A AR044614A1 (es) | 2003-06-05 | 2004-06-04 | Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4) |
Country Status (11)
Country | Link |
---|---|
US (1) | US20060122195A1 (es) |
EP (1) | EP1633729B1 (es) |
JP (1) | JP2006526618A (es) |
AR (1) | AR044614A1 (es) |
AT (1) | ATE402928T1 (es) |
DE (1) | DE602004015451D1 (es) |
ES (1) | ES2309539T3 (es) |
SE (1) | SE0301653D0 (es) |
TW (1) | TW200505875A (es) |
UY (1) | UY28348A1 (es) |
WO (1) | WO2004108692A1 (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI328007B (en) * | 2002-01-16 | 2010-08-01 | Astrazeneca Ab | Novel compounds |
SE0301650D0 (sv) * | 2003-06-04 | 2003-06-04 | Astrazeneca Ab | Novel compounds |
SE0301654D0 (sv) * | 2003-06-05 | 2003-06-05 | Astrazeneca Ab | Novel compounds |
BRPI0610035A2 (pt) * | 2005-04-21 | 2010-05-18 | Serono Lab | sulfonamidas de pirazina 2,3 substituìdas |
KR101333861B1 (ko) | 2005-05-24 | 2013-11-28 | 메르크 세로노 에스. 에이. | Crth2 조정자로서 삼환계 스피로 유도체 |
TW200745060A (en) * | 2005-09-19 | 2007-12-16 | Astrazeneca Ab | Novel process |
TW200800921A (en) * | 2005-09-19 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
EP1970373A1 (en) * | 2005-12-02 | 2008-09-17 | Mitsubishi Tanabe Pharma Corporation | Alicyclic heterocyclic compound |
US20090182142A1 (en) * | 2005-12-02 | 2009-07-16 | Shigeru Furukubo | Aromatic Compound |
TW200730512A (en) * | 2005-12-12 | 2007-08-16 | Astrazeneca Ab | Novel compounds |
US7829709B1 (en) | 2007-08-10 | 2010-11-09 | Marquette University | Cysteine prodrugs to treat schizophrenia and drug addiction |
GB0718167D0 (en) | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
WO2009100431A1 (en) | 2008-02-07 | 2009-08-13 | Marquette University | Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings |
JP5658137B2 (ja) * | 2008-04-16 | 2015-01-21 | マーケット ユニバーシティー | 統合失調症又は薬物渇望治療用医薬組成物 |
WO2011076699A1 (de) | 2009-12-21 | 2011-06-30 | Bayer Cropscience Ag | Bis(difluormethyl)pyrazole als fungizide |
US8815775B2 (en) | 2010-05-18 | 2014-08-26 | Bayer Cropscience Ag | Bis(difluoromethyl)pyrazoles as fungicides |
AU2013225938B2 (en) * | 2012-02-29 | 2017-08-10 | Chemocentryx, Inc. | Pyrazol-1-yl benzene sulfonamides as CCR9 antagonists |
US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
HUE045725T2 (hu) | 2014-02-13 | 2020-01-28 | Incyte Corp | Ciklopropilaminok mint LSD1 inhibitorok |
AU2015217073B2 (en) | 2014-02-13 | 2019-08-22 | Incyte Holdings Corporation | Cyclopropylamines as LSD1 inhibitors |
EP3392244A1 (en) | 2014-02-13 | 2018-10-24 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為lsd1抑制劑之咪唑并吡啶及咪唑并吡嗪 |
WO2016007736A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
WO2016057424A1 (en) | 2014-10-06 | 2016-04-14 | Chemocentryx, Inc. | Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies |
TWI714567B (zh) | 2015-04-03 | 2021-01-01 | 美商英塞特公司 | 作為lsd1抑制劑之雜環化合物 |
MY189367A (en) | 2015-08-12 | 2022-02-08 | Incyte Corp | Salts of an lsd1 inhibitor |
EP3445339B1 (en) | 2016-04-22 | 2023-08-23 | Incyte Corporation | Formulations of an lsd1 inhibitor |
BR112020009055A2 (pt) | 2017-11-06 | 2020-11-03 | Rapt Therapeutics, Inc. | moduladores de receptor de quimiocina para tratamento de câncer positivo para vírus epstein barr |
US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
US10792360B1 (en) | 2019-11-21 | 2020-10-06 | Chemocentryx, Inc. | Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5962490A (en) * | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
GB9512697D0 (en) * | 1995-06-22 | 1995-08-23 | Zeneca Ltd | Heterocyclic compounds |
US7091201B2 (en) * | 2000-09-25 | 2006-08-15 | Actelion Pharmaceuticals Ltd. | Arylalkane-sulfonamides having endothelin-antagonist activity |
WO2002030357A2 (en) * | 2000-10-11 | 2002-04-18 | Chemocentryx, Inc. | Compounds and methods for modulating ccr4 function |
US7410972B2 (en) * | 2001-12-18 | 2008-08-12 | Astrazeneca Ab | Compounds |
TWI328007B (en) * | 2002-01-16 | 2010-08-01 | Astrazeneca Ab | Novel compounds |
WO2004007472A1 (ja) * | 2002-07-10 | 2004-01-22 | Ono Pharmaceutical Co., Ltd. | Ccr4アンタゴニストおよびその医薬用途 |
SE0301650D0 (sv) * | 2003-06-04 | 2003-06-04 | Astrazeneca Ab | Novel compounds |
SE0301654D0 (sv) * | 2003-06-05 | 2003-06-05 | Astrazeneca Ab | Novel compounds |
-
2003
- 2003-06-05 SE SE0301653A patent/SE0301653D0/xx unknown
-
2004
- 2004-05-27 TW TW093115166A patent/TW200505875A/zh unknown
- 2004-06-02 US US10/559,312 patent/US20060122195A1/en not_active Abandoned
- 2004-06-02 WO PCT/SE2004/000850 patent/WO2004108692A1/en active Application Filing
- 2004-06-02 JP JP2006508570A patent/JP2006526618A/ja active Pending
- 2004-06-02 DE DE602004015451T patent/DE602004015451D1/de not_active Expired - Fee Related
- 2004-06-02 EP EP04748975A patent/EP1633729B1/en not_active Not-in-force
- 2004-06-02 AT AT04748975T patent/ATE402928T1/de not_active IP Right Cessation
- 2004-06-02 ES ES04748975T patent/ES2309539T3/es active Active
- 2004-06-04 AR ARP040101943A patent/AR044614A1/es unknown
- 2004-06-04 UY UY28348A patent/UY28348A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1633729A1 (en) | 2006-03-15 |
TW200505875A (en) | 2005-02-16 |
WO2004108692A1 (en) | 2004-12-16 |
SE0301653D0 (sv) | 2003-06-05 |
JP2006526618A (ja) | 2006-11-24 |
EP1633729B1 (en) | 2008-07-30 |
DE602004015451D1 (de) | 2008-09-11 |
UY28348A1 (es) | 2005-01-31 |
ATE402928T1 (de) | 2008-08-15 |
ES2309539T3 (es) | 2008-12-16 |
US20060122195A1 (en) | 2006-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR044614A1 (es) | Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4) | |
AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
AR057131A1 (es) | Derivados de purina como inmunomodulador | |
AR047817A1 (es) | Derivados de aril- y heteroarilpiperidincarboxilatos, su preparacion y su aplicacion en terapeutica | |
AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
AR063804A1 (es) | Compuestos de azoniabiciclo[2.2.2]octano | |
AR039124A1 (es) | Derivados de adamantano, procedimiento de preparacion y composiciones farmaceuticas que los contienen | |
AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
AR042024A1 (es) | Compuestos farmaceuticos derivados de piridona, pirimidona y pirazinona | |
AR039659A1 (es) | Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida metaloproteinasa | |
AR062640A1 (es) | Compuestos de azolcarboxamidas y composiciones herbicidas | |
AR053405A1 (es) | Derivados de urea sustituidas, composiciones farmaceuticas y metodos para el tratamiento de cardiopatias | |
CO5670358A2 (es) | Derivados de 2-piridona como inhibidores de la elastasa neutrofila y su uso | |
AR049263A1 (es) | Heterociclos biciclicos inhibidores de quinasa utiles como agentes anticancer | |
AR081331A1 (es) | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos | |
AR069813A1 (es) | Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento | |
AR057380A1 (es) | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos | |
AR084768A1 (es) | Moduladores de la senda de complemento y usos de los mismos | |
AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
AR041260A1 (es) | Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia | |
PE20090042A1 (es) | Analogos de ciclopamina | |
AR038179A1 (es) | Fenilsulfonamidas para uso terapeutico | |
AR046394A1 (es) | Derivados de quinolinas y quinazolinas, metodo de preparacion de los mismos y composiciones farmaceuticas que los contienen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |